Den europeiske union - litauisk - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Den europeiske union - litauisk - EMA (European Medicines Agency)

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - imuninės serumai ir imunoglobulinai, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.

Den europeiske union - litauisk - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - daugybinė mieloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Den europeiske union - litauisk - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - daugybinė mieloma - antinavikiniai vaistai - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Den europeiske union - litauisk - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatos navikai, kastracija-atsparus - antinavikiniai vaistai - treatment of adult patients with prostate cancer.

Den europeiske union - litauisk - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - respiraciniu sincitijaus infekcijos - vakcinos - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

Den europeiske union - litauisk - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - daugybinė mieloma - antinavikiniai vaistai - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Den europeiske union - litauisk - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegravir - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 ir 5.

Den europeiske union - litauisk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - aripiprazolas - Šizofrenija - psicholeptikai - Šizofrenijos palaikomuoju gydymu suaugusiems pacientams, stabilizuotam su geriamuoju aripiprazolu.

Den europeiske union - litauisk - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antinavikiniai vaistai - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.